首页> 美国卫生研究院文献>European Journal of Human Genetics >Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on ‘black bone disease in Italy
【2h】

Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on ‘black bone disease in Italy

机译:在99例蛋白尿患者中鉴定出十二种新型HGD基因变体:关注意大利的黑骨病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Alkaptonuria (AKU) is an autosomal recessive disorder caused by mutations in homogentisate-1,2-dioxygenase (HGD) gene leading to the deficiency of HGD enzyme activity. The DevelopAKUre project is underway to test nitisinone as a specific treatment to counteract this derangement of the phenylalanine-tyrosine catabolic pathway. We analysed DNA of 40 AKU patients enrolled for SONIA1, the first study in DevelopAKUre, and of 59 other AKU patients sent to our laboratory for molecular diagnostics. We identified 12 novel DNA variants: one was identified in patients from Brazil (c.557T>A), Slovakia (c.500C>T) and France (c.440T>C), three in patients from India (c.469+6T>C, c.650–85A>G, c.158G>A), and six in patients from Italy (c.742A>G, c.614G>A, c.1057A>C, c.752G>A, c.119A>C, c.926G>T). Thus, the total number of potential AKU-causing variants found in 380 patients reported in the HGD mutation database is now 129. Using mCSM and DUET, computational approaches based on the protein 3D structure, the novel missense variants are predicted to affect the activity of the enzyme by three mechanisms: decrease of stability of individual protomers, disruption of protomer-protomer interactions or modification of residues in the region of the active site. We also present an overview of AKU in Italy, where so far about 60 AKU cases are known and DNA analysis has been reported for 34 of them. In this rather small group, 26 different HGD variants affecting function were described, indicating rather high heterogeneity. Twelve of these variants seem to be specific for Italy.
机译:碱性磷酸酶尿症(AKU)是一种常染色体隐性遗传疾病,由高尿酸1,2-双加氧酶(HGD)基因突变引起,导致HGD酶活性不足。 DevelopAKUre项目正在进行中,以测试尼替尼酮作为抵消苯丙氨酸-酪氨酸分解代谢途径的这种紊乱的一种特殊治疗方法。我们分析了40名参加SO​​NIA1的AKU患者的DNA,这是DevelopAKUre中的第一项研究,另外还有59名送往我们实验室进行分子诊断的AKU患者的DNA。我们鉴定了12种新颖的DNA变异:在巴西(c.557T> A),斯洛伐克(c.500C> T)和法国(c.440T> C)的患者中鉴定出了一种,在印度(c.469 + 6T> C,c.650-85A> G,c.158G> A),来自意大利的六名患者(c.742A> G,c.614G> A,c.1057A> C,c.752G> A, c.119A> C,c.926G> T)。因此,在HGD突变数据库中报告的380位患者中发现的潜在AKU致病变体总数现在为129。使用mCSM和DUET,基于蛋白质3D结构的计算方法,新的错义变体预计会影响AKU的活性。通过三种机制降低酶的活性:降低单个启动子的稳定性,破坏启动子与启动子的相互作用或修饰活性位点区域中的残基。我们还介绍了意大利的AKU概况,到目前为止,已知AKU案例约60例,其中有34例进行了DNA分析。在这个相当小的小组中,描述了影响功能的26种不同的HGD变体,表明其异质性很高。这些变体中的十二个似乎是特定于意大利的。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号